Global Recombinant Vaccines Market Size By Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), By Disease (Hepatitis B, Sexually Transmitted Diseases, Cancer), By Geographic Scope And Forecast

Recombinant Vaccines Market Size And Forecast

Recombinant Vaccines Market size was valued at USD 47.44 Billion in 2021 and is projected to reach USD 88.68 Billion by 2030, growing at a CAGR of 7.30% from 2023 to 2030.

The increasing concerns about the spread of infectious diseases in the changing environment. These infectious diseases are a load on public health but have also an impact on global economies. New diseases such as hepatitis, HIV, and dengue have pulled a huge concern for the government of worldwide countries. There is also a resurgence of diseases that seemed to be under control such as malaria, cholera, and many more. Thus, the rising prevalence of infectious diseases is expected to boost the growth of the global Recombinant Vaccines Market. The Global Recombinant Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Recombinant Vaccines Market Definition

The manufacturing of vaccines initially was on an empirical basis, relying on the attenuation or inactivation of pathogens. The emergence of gene-splicing, genomics, and recombinant deoxyribonucleic acid technology has revolutionized vaccine development lately by introducing vaccines within the market. These vaccines are genetically engineered and produced in the laboratory by eradicating the danger of infectious viral antigens, assuring vaccine effectiveness and safety. The recombinant vaccine is developed through the appliance of recombinant deoxyribonucleic acid technology.

Recombinant vaccines are developed using an expression system such as yeast, bacteria, mammalian cells, etc. to precise the antigenic protein component. DNA encoding the antigenic determinant is inserted into such an expressing system which further develops an immune reaction after the antigen expression. Such vaccines are designed for the recombinant expression of proteins and viral vectors. Recombinant vaccines are developed as an answer to combat emerging and re-emerging viral infections.

Global Recombinant Vaccines Market Overview

The increase in the incidence of zoonotic diseases and emerging technologies are driving the global Recombinant Vaccines Market. There is a constant increase in diseases caused by bacteria or viruses such as swine flu, malaria, HPV, and other diseases, which has raised the demand for vaccination and led to the eradication of diseases such as polio in a few countries. With the advancement in technology, there is development in vaccines, which are more useful than conventional vaccines and does not lead to any side effect. These vaccines are easy to administer in the body orally, intramuscularly, or intradermally.

Moreover, continuous investment in research & development for the development of new vaccines and increased awareness and pet adoption has positively anticipated propelling the growth of the global Recombinant Vaccines Market. However, there are certain barriers faced that will hinder the overall market growth. The factors such as the high cost associated with the per dose of the vaccine to limit adoption are limiting the market growth. Nevertheless, the advancements in technologies, increasing support for vaccine development, and untapped potential in emerging markets offer favorable growth opportunities.

Furthermore, the market growth is driven by the rise in R&D activities for recombinant vaccines, the increasing prevalence of infectious diseases, and the rising rates of vaccinations globally. Additionally, rising product approvals also propel the growth of the Recombinant Vaccines Market. For instance, in 2021, Sanofi and Merck got approval for a six-in-one pediatric combination vaccine in the United States. Also, the potential growth in untapped emerging nations creates lucrative opportunities for the market to grow during the forecast period.

Global Recombinant Vaccines Market Segmentation Analysis

The Global Recombinant Vaccines Market is segmented based on Type, Disease, and Geography.

Recombinant Vaccines Market, By Type

• Subunit Recombinant Vaccines
• Attenuated Recombinant Vaccines
• Vector Recombinant Vaccines

Based on Type, the market is bifurcated into Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, and Vector Recombinant Vaccines. The subunit recombinant vaccines segment holds the largest market share during the forecast period. Recombinant subunit vaccines comprise only the recombinant protein, excluding the infectious virus, thus shielding the risk of viral diseases. The introduction of recombinant subunit vaccines has fostered new perspectives for manufacturers to rise against viral antigens.

Recombinant Vaccines Market, By Disease

• Hepatitis B
• Sexually Transmitted Diseases
• Cancer
• Others

Based on Disease, the market is bifurcated into Hepatitis B, Sexually Transmitted Diseases, Cancer, and Others. The hepatitis B segment holds the largest market share during the forecast period. The factors that can be attributed to the growing prevalence of hepatitis B in emerging and underdeveloped countries and the launch of effective hepatitis B vaccines are accelerating the demand for this segment.

Recombinant Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of The World

On the basis of Regional Analysis, the Global Recombinant Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America holds the largest market share. The continuous R&D investments by key players, the rapid adoption of efficient vaccines across the region, the availability of advanced molecular & genetic engineering instruments in the region, and ongoing projects will increase the market in the North American sphere.

Key Players

The “Global Recombinant Vaccines Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as GlaxoSmithKline, Sanofi, Novartis AG, Merck & Co. Inc, Pfizer Inc., Bharat Biotech, Bayer AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• On March 2020, Pfizer collaborated with BioNTech to advance the development of the mRNA vaccine for coronavirus infection.
• On March 2019, Merck & Company Inc. worked on new TB drugs for people suffering from tuberculosis, increasing vaccine research development and raising market growth.
• On May 2019, Sanofi received USFDA approval for Dengvaxia, a live attenuated dengue vaccine.
• On December 2019, Merck received approval from the USFDA for a new vaccine. The ERVEBO is the first-ever Ebola vaccine.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into Active, Cutting Edge, Emerging, and Innovators categories.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Recombinant Vaccines Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the global Recombinant Vaccines Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

<a href="https//www.mark